Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 30, 2024

Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb

RRID:AB_2096270
Type: Antibody

Proper Citation

(Cell Signaling Technology Cat# 3777 (also 3777S, 3777T, 3777P), RRID:AB_2096270)

Antibody Information

URL: http://antibodyregistry.org/AB_2096270

Proper Citation: (Cell Signaling Technology Cat# 3777 (also 3777S, 3777T, 3777P), RRID:AB_2096270)

Target Antigen: Phospho-EGF Receptor (Tyr1068)

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: W, IHC-P, IF-IC, F
Consolidation: AB_2277657
Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE

Antibody Name: Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb

Description: This recombinant monoclonal targets Phospho-EGF Receptor (Tyr1068)

Target Organism: human, mouse, rat

Clone ID: D7A5

Antibody ID: AB_2096270

Vendor: Cell Signaling Technology

Catalog Number: 3777 (also 3777S, 3777T, 3777P)

Alternative Catalog Numbers: 3777P, 3777S, 3777T

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:FALSE, Functional in animal:FALSE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development

No alerts have been found for Phospho-EGF Receptor (Tyr1068) (D7A5) XP Rabbit mAb.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 98 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Developmental cell, 59(5), 579.

Popovi? L, et al. (2024) Profiling of ERBB receptors and downstream pathways reveals selectivity and hidden properties of ERBB4 antagonists. iScience, 27(2), 108839.

Zhang Q, et al. (2024) EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis. Cell reports, 43(2), 113714.

Dobersberger M, et al. (2024) An engineering strategy to target activated EGFR with CAR T cells. Cell reports methods, 100728.

Mucciolo G, et al. (2024) EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer cell, 42(1), 101.

Iyer RS, et al. (2024) Drug-resistant EGFR mutations promote lung cancer by stabilizing interfaces in ligand-free kinase-active EGFR oligomers. Nature communications, 15(1), 2130.

Müller L, et al. (2023) Plakophilin 3 facilitates G1/S phase transition and enhances proliferation by capturing RB protein in the cytoplasm and promoting EGFR signaling. Cell reports, 42(1), 112031.

Glover JD, et al. (2023) The developmental basis of fingerprint pattern formation and variation. Cell, 186(5), 940.

Rosenberg SC, et al. (2023) Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation. Cell chemical biology.

Zhang X, et al. (2023) IGFBP3 induced by the TGF-?/EGFRvIII transactivation contributes to the malignant phenotype of glioblastoma. iScience, 26(5), 106639.

Wu F, et al. (2023) Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes. EBioMedicine, 87, 104410.

Jiang Q, et al. (2023) HPIP is an essential scaffolding protein running through the EGFR-RAS-ERK pathway and drives tumorigenesis. Science advances, 9(23), eade1155.

Bhattacharjee D, et al. (2023) Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor. Cell chemical biology, 30(10), 1211.

Pan Y, et al. (2023) KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer cell, 41(1), 88.

Pardo-Pastor C, et al. (2023) Piezo1 activates noncanonical EGFR endocytosis and signaling. Science advances, 9(39), eadi1328.

Ko A, et al. (2023) LZTR1 Mutation Mediates Oncogenesis through Stabilization of EGFR and AXL. Cancer discovery, 13(3), 702.

de Miguel FJ, et al. (2023) Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. Cancer cell, 41(8), 1516.

Choi YR, et al. (2023) Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. British journal of cancer.

Hondo N, et al. (2023) MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. Cancer letters, 567, 216264.

Rizzo S, et al. (2023) Promoting the activity of a receptor tyrosine phosphatase with a novel pH-responsive transmembrane agonist inhibits cancer-associated phenotypes. Protein science : a publication of the Protein Society, 32(9), e4742.